Get the Daily Brief
Latest Biotech News
Cell therapy for liver disease—University of Edinburgh reports new cell-based approach
Researchers at the University of Edinburgh advanced a new cell-therapy strategy aimed at treating advanced liver disease, targeting patients facing dire outcomes from cirrhosis and liver failure....
Targeted protein degradation—HDAC4 PROTAC pushes ferroptosis plus radiation in lung cancer
A research team described an HDAC4-specific PROTAC degrader designed to enhance radiation therapy in lung cancer by boosting ferroptosis. The work centers on targeted protein degradation of...
Oncology trial signals—durvalumab plus anlotinib maintenance tested in ES-SCLC DURABLE study
A multicenter, randomized phase II trial named DURABLE reported results suggesting a maintenance regimen of durvalumab plus anlotinib outperformed durvalumab monotherapy in extensive-stage...
Immuno-metabolic regulation in obesity—GPSM1 constrains CD73+CD103+ Tregs and obesity damage
Researchers identified GPSM1 as a molecular regulator that limits a specific subset of regulatory T cells—CD73+CD103+ Tregs—within adipose tissue, shaping obesity-related immune damage. The study...
Neuro-oncology platform and mechanistic neurobiology—dual-target machine-learning DBS for Parkinson’s
Researchers presented a machine learning framework to optimize dual-target deep brain stimulation (DBS) in Parkinson’s disease, aiming to better target both the subthalamic nucleus (STN) and...
Translational genomics and cardiometabolic risk—phenome-wide links second-line diabetes drugs to outcomes
A phenome-wide study used data from the All of Us research program to connect second-line diabetes therapies with downstream health outcomes. The analysis, led by Salvatore, Zhang, Tang and...
Biomarkers after cancer diagnosis—Nature Communications ties trajectories to heart risk
A Nature Communications study linked post-cancer biomarker trajectories—including metabolic and inflammatory markers—to later cardiovascular disease (CVD) risk. The report describes how biomarker...
Drug discovery and computation—Isomorphic Labs unveils Drug Design Engine beyond AlphaFold
Isomorphic Labs introduced the Isomorphic Labs Drug Design Engine (IsoDDE), positioning it as a next step beyond structure-only predictions from AlphaFold 3. The company says IsoDDE more than...
FDA approvals and oncology pipeline momentum
The FDA has granted accelerated approval to BeOne Medicines’ Beqalzi (sonrotoclax), marking the first BCL2 inhibitor approved specifically for relapsed or refractory mantle cell lymphoma after at...
Breast cancer treatment expansion via antibody drug conjugates
AstraZeneca and Daiichi Sankyo have secured FDA approval for a new first-line option in triple-negative breast cancer, according to the latest report. The antibody drug conjugate was developed...
PROTAC progress turns into an FDA milestone
Vepdegestrant (Veppanu®) has been described as the first FDA-approved PROTAC therapy, following a May 2026 approval. The oral, CRBN-recruiting PROTAC works by catalytically degrading WT and...
Gene editing for cholesterol via Verve’s VERV-102 acquisition
Eli Lilly said its gene-editing therapy VERV-102 reduced cholesterol levels by 62% in participants in an early clinical study, delivering an early signal for a one-time treatment approach to lower...
Cell therapy for advanced liver disease moves toward clinical translation
Researchers at the University of Edinburgh have advanced a cell therapy approach for advanced liver disease, aiming to repair damaged tissue in patients facing cirrhosis and liver failure. The...
Clinical trial readouts shaping next oncology discussions
A DURABLE phase II trial is reported to have found that maintenance treatment with durvalumab plus anlotinib outperformed durvalumab alone in extensive-stage small-cell lung cancer, according to...
Cancer biology reveals new mechanism of radiotherapy resistance
Pancreatic cancer researchers identified ATP2B4 as a driver of radiotherapy resistance through effects on chromatin compaction, according to the provided research report. The study links a...
Companion science: macrophage-driven liver disease progression in MASLD
Using spatial multi-omics, researchers reported shifting macrophage populations across MASLD progression and identified markers that may support patient stratification in clinical trials. The...
Precision medicine scaling faces reimbursement and data integration challenges
A UPMC report says that while many health systems now offer precision medicine programs, scaling remains constrained by reimbursement, data integration, and patient engagement. The findings argue...
Next-gen diabetes drug safety signals via phenome-wide analysis
A phenome-wide study using All of Us research program data linked second-line diabetes drugs to specific downstream health outcomes, according to the provided research description. The analysis...
Regulatory approval: targeted protein degradation enters first FDA-backed oncology use
Vepdegestrant (Veppanu) — an oral CRBN-recruiting PROTAC from Array/ARV-471 — became the first FDA-approved PROTAC therapy in May 2026, marking a regulatory milestone for targeted protein...
FDA approval: sonrotoclax expands BCL2 inhibitor therapy in mantle cell lymphoma
FDA granted accelerated approval to Beqalzi (sonrotoclax), the first BCL2 inhibitor approved specifically for relapsed or refractory mantle cell lymphoma in adults after at least two prior lines...